Find Drugs for Pulmonary/Respiratory Diseases in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB001

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 07, 2020

            Details:

            Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Genistein

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Humanetics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 19, 2020

            Details:

            Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Etokimab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ANB020

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 08, 2020

            Details:

            AnaptysBio presented full data from its Phase 2a proof-of-concept clinical trial of etokimab in adult patients with severe eosinophilic asthma at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB001

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sargramostim

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Leukine

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement August 04, 2020

            Details:

            Funding will support two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Razuprotafib

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: MTEC

            Deal Size: $5.1 million Upfront Cash: Undisclosed

            Deal Type: Funding August 04, 2020

            Details:

            Aerpio is developing a selective small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, razuprotafib (AKB-9778), that restores Tie2 pathway activation in endothelial cells to stabilize blood vessels during vascular injury and inflammation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Genistein

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding July 23, 2020

            Details:

            Funding will be used to conduct a placebo-controlled double-blind study to understand if 12 weeks of BIO 300 can mitigate lasting COVID-19 effects in the lungs and improve the quality of life for patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alidornase alfa

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRX–110

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Protalix BioTherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 23, 2020

            Details:

            The arrangement, if consummated, would relate to the development and commercialization of PRX–110, or alidornase alfa, for the treatment of Pulmonary Sarcoidosis and related diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ANG-3777

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ANG-3777

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levosimendan

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering July 06, 2020

            Details:

            Tenax currently intends to use the net proceeds from the offerings to further its clinical trials of levosimendan, for research and development and general corporate purposes, including working capital and potential acquisitions.

            PharmaCompass